Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 14/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647846 | 0.86 | CCR5 (0.62) | CCR5LRRK2STAT3PTGER1 | |
| SCHEMBL5699793 | 0.83 | CCR5 (0.58) | CCR5LRRK2STAT3NPSR1SLC6A4 | |
| SCHEMBL1646798 | 0.83 | CCR5 (0.58) | CCR5LRRK2STAT3NPSR1SLC6A4 | |
| SCHEMBL5699779 | 0.80 | CCR5 (0.58) | CCR5LRRK2STAT3NPSR1SLC6A4 | |
| SCHEMBL5699892 | 0.79 | CCR5 (0.62) | CCR5LRRK2STAT3NPSR1SLC6A4 | |
| SCHEMBL5699883 | 0.77 | CCR5 (0.57) | CCR5LRRK2STAT3NPSR1SLC6A4 | |
| SCHEMBL18920768 | 0.76 | CCR5 (0.64) | CCR5STAT3NPSR1SLC6A4 | |
| SCHEMBL13321705 | 0.75 | CCR5 (0.68) | CCR5STAT3NPSR1SLC6A4 | |
| SCHEMBL29689869 | 0.75 | CCR5 (0.63) | CCR5STAT3NPSR1SLC6A4 | |
| SCHEMBL5699666 | 0.75 | CCR5 (0.63) | CCR5STAT3NPSR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687268-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-09 | — | — | EP | claimed |
| WO-2005047249-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-26 | — | — | WO | claimed |
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | US | claimed |
| EP-1687268-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047249-A1 | BENZYLETHER AMINE COMPOUNDS USEFUL AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101644-A1 | Benzylether amine compounds useful as CCR-5 antagonists | CCR1, CCR3, CCR4 | CCR5 7/4885LRRK2 1531/4885STAT3 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.